[Skip to Navigation]
Sign In

April 2021 - July 1883

Decade

Year

Issue

March 3, 2020, Vol 323, No. 9, Pages 809-902 | Drug Pricing

In This Issue of JAMA

Audio Highlights

Abstract Full Text
free access online only has audio
JAMA. 2020;323(9):e200011. doi:10.1001/jama.2020.0011
Original Investigation

Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies

Abstract Full Text
free access has active quiz
JAMA. 2020;323(9):834-843. doi:10.1001/jama.2020.0442

This study uses data from annual financial reports to compare the profitability of large pharmaceutical companies vs other large companies in the S&P 500 Index from 2000 to 2018, measured via gross profit; earnings before interest, taxes, depreciation, and amortization; and net income (earnings).

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

Abstract Full Text
free access has active quiz
JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166

This study uses publicly available data to analyze research and development spending to win FDA approval and bring new drugs to market between 2009 and 2018.

Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018

Abstract Full Text
free access
JAMA. 2020;323(9):854-862. doi:10.1001/jama.2020.1012

This study describes changes in list prices, net prices, and discounts for branded pharmaceutical products in the US between 2007 and 2018 and estimates the extent to which list price increases were offset by increases in discounts.

US Health Care Spending by Payer and Health Condition, 1996-2016

Abstract Full Text
free access has active quiz
JAMA. 2020;323(9):863-884. doi:10.1001/jama.2020.0734

This study estimates health care spending for the most common health conditions in the United States, including low back pain and musculoskeletal disorders, diabetes, and ischemic heart disease, between 1996 and 2016.

Research Letter

Sponsorship and Funding for Gene Therapy Trials in the United States

Abstract Full Text
free access
JAMA. 2020;323(9):890-891. doi:10.1001/jama.2019.22214

This study characterizes government, academia, and private funding for gene therapy trials in the United States by technology type and therapeutic and disease area.

Viewpoint

Drug Shortages in the United States: Are Some Prices Too Low?

Abstract Full Text
JAMA. 2020;323(9):819-820. doi:10.1001/jama.2019.20504

This Viewpoint discusses underlying causes of generic drug shortages in the United States and proposes solutions to address those shortages, including financial incentives for manufacturers that provide a steady supply of high-quality products.

Expanding Access and Reducing Prices for Drugs to Prevent HIV: Should Government Enforce Its Patent Rights Against the Pharmaceutical Industry?

Abstract Full Text
JAMA. 2020;323(9):821-822. doi:10.1001/jama.2019.22357

This Viewpoint considers the lawsuit United States v Gilead Sciences in the context of intellectual property rights and the patents held on medications for preexposure prophylaxis (PrEP) for HIV infection, leading to a trade-off between affordability and future pharmaceutical collaboration and innovation.

The Probiotic Conundrum: Regulatory Confusion, Conflicting Studies, and Safety Concerns

Abstract Full Text
JAMA. 2020;323(9):823-824. doi:10.1001/jama.2019.22268

This Viewpoint characterizes reasons for the lack of evidence about the health effects of probiotic supplements and cautions against a “can’t hurt, can’t help” presumption made by consumers and clinicians.

A Piece of My Mind

The Secret About Achieving Your Dreams

Abstract Full Text
has audio
JAMA. 2020;323(9):825. doi:10.1001/jama.2020.1033

In this narrative medicine essay, a 35-year-old psychiatrist reflects on his dreams in childhood, as an academic, and as a parent of a young child as he faces his own mortality.

Editorial

Relentless Prescription Drug Price Increases

Abstract Full Text
JAMA. 2020;323(9):826-828. doi:10.1001/jama.2020.0359

Are Pharmaceutical Companies Earning Too Much?

Abstract Full Text
JAMA. 2020;323(9):829-830. doi:10.1001/jama.2020.0351

Affording Medicines for Today’s Patients and Sustaining Innovation for Tomorrow

Abstract Full Text
JAMA. 2020;323(9):831-833. doi:10.1001/jama.2020.0167
JAMA Clinical Guidelines Synopsis

Diagnosis and Treatment of Adults With Community-Acquired Pneumonia

Abstract Full Text
has audio
JAMA. 2020;323(9):885-886. doi:10.1001/jama.2019.21118

This JAMA Guidelines Synopsis summarizes the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) 2019 recommendations on diagnosis and treatment of adults with community-acquired pneumonia.

From The Medical Letter on Drugs and Therapeutics

Corticosteroids in Community-Acquired Pneumonia

Abstract Full Text
JAMA. 2020;323(9):887-888. doi:10.1001/jama.2020.0216

This Medical Letter review summarizes evidence underlying American Thoracic Society and Infectious Diseases Society of America guideline recommendations on the use of corticosteroids as an adjunct to antimicrobials for the treatment of community-acquired pneumonia

Medical News & Perspectives

Rebates—The Little-Known Factor Behind Increasing Drug List Prices

Abstract Full Text
JAMA. 2020;323(9):812-813. doi:10.1001/jama.2020.1208

This Medical News story examines the role of rebates in drug pricing.

News From the Food and Drug Administration

FDA Policies Address Development of Gene Therapies

Abstract Full Text
JAMA. 2020;323(9):817. doi:10.1001/jama.2020.1784

New Nonsurgical Option Approved for Thyroid Eye Disease

Abstract Full Text
JAMA. 2020;323(9):817. doi:10.1001/jama.2020.1480

Drug Approved to Aid Youths With Peanut Allergy

Abstract Full Text
JAMA. 2020;323(9):817. doi:10.1001/jama.2020.1785
The JAMA Forum

Rising Prices and Health Care “Empires”

Abstract Full Text
free access
JAMA. 2020;323(9):815-816. doi:10.1001/jama.2020.1370
Bench to Bedside

New Insight on Preventing EGFR Inhibitor–Induced Adverse Effects

Abstract Full Text
JAMA. 2020;323(9):814. doi:10.1001/jama.2020.0812
Poetry and Medicine

After a Long Illness

Abstract Full Text
JAMA. 2020;323(9):897. doi:10.1001/jama.2019.21841
JAMA Revisited

Toxics

Abstract Full Text
JAMA. 2020;323(9):898. doi:10.1001/jama.2019.13334
JAMA Patient Page

“Surprise” Out-of-Network Medical Bills

Abstract Full Text
free access
JAMA. 2020;323(9):902. doi:10.1001/jama.2020.0847

This JAMA Patient Page discusses the issue of surprise medical bills and what steps patients can take to protect themselves from receiving them.

Comment & Response

Strategies to Avoid Extubation Failure Among ICU Patients

Abstract Full Text
JAMA. 2020;323(9):891-892. doi:10.1001/jama.2019.21951

Strategies to Avoid Extubation Failure Among ICU Patients—Reply

Abstract Full Text
JAMA. 2020;323(9):892-893. doi:10.1001/jama.2019.21954

Informed Consent for Stem Cell–Based Interventions

Abstract Full Text
JAMA. 2020;323(9):893. doi:10.1001/jama.2019.22238

Informed Consent for Stem Cell–Based Interventions—Reply

Abstract Full Text
JAMA. 2020;323(9):894. doi:10.1001/jama.2019.22271

Wasteful Health Care Spending in the United States

Abstract Full Text
JAMA. 2020;323(9):894-895. doi:10.1001/jama.2019.22252

Wasteful Health Care Spending in the United States

Abstract Full Text
JAMA. 2020;323(9):895. doi:10.1001/jama.2019.22255

Wasteful Health Care Spending in the United States—Reply

Abstract Full Text
JAMA. 2020;323(9):895-896. doi:10.1001/jama.2019.22265
Correction

Incorrect Wording

Abstract Full Text
free access
JAMA. 2020;323(9):896. doi:10.1001/jama.2020.1367
JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2020;323(9):809-810. doi:10.1001/jama.2019.13327
×